Introduction
Cardiovascular diseases (CVDs) are the leading cause of death and disability globally [
1,
2]. The overall prevalence of CVD has almost doubled with 271 million cases in 1990 to 523 million cases in 2019, and the number of deaths from CVD has steadily increased from 12.1 million in 1990 to 18.6 million in 2019 [
2,
3]. Despite significant progress in drug treatment and interventional therapy in recent years, the number of deaths from CVD remains the highest, demonstrating a serious threat to public health. Thus, early identification of individuals with high risk of CVD will contribute to preventing disease progression.
Atherogenic Index of Plasma (AIP) is a new identified and lipid metabolism associated biomarker panel of plasma atherogenicity, which is calculated by the log-transformed ratio of Triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) in molar concentrations [
4]. AIP was correlated with lipoprotein particle size and fractional esterification rate of HDL cholesterol (FERHDL) [
5], which was closely related to insulin resistance [
6,
7]. One study with 17,382 adult participants from the National Health and Nutrition Examination Survey (NHANES) had demonstrated high AIP was associated with 1.17-fold and 1.26-fold increased risk of all-cause mortality and CVD-specific mortality, respectively [
8]. Subsequently another Kailuan study that collected 54,440 participants after 11.05 years of follow-up showed that participants with the highest levels of AIP had a significantly increased risk of myocardial infarction [
9]. Alifu et al. studied an 8-fold increased risk of major adverse cardiovascular events in participants with chronic coronary syndromes compared to those with low AIP, suggesting that AIP also has significant prognostic predictive power in patients with CVD [
10]. Most of these studies have focused on researching the relationship between AIP levels as a predictor of the incidence of various cardiovascular diseases (e.g., myocardial infarction and coronary heart disease) and the prognosis of patients with cardiovascular disease, suggesting that AIP is a strong predictive biomarker of the incidence of cardiovascular disease or the prognosis of patients with related diseases [
8‐
10].
Indeed, AIP has been demonstrated to be a significant predictor of incident pre-diabetes or diabetes [
11]. Glucose metabolism abnormality is prevalent in individuals with established CVD. Compared with normal glucose metabolism, individuals with type 2 diabetes mellitus (T2DM) and pre-diabetes are also significantly associated with poor outcomes among CVD individuals [
12,
13]. Therefore, early identification of modifiable cardiovascular risk factors among individuals with abnormal glucose metabolism (a collective term for diabetes mellitus and pre-diabetes mellitus) will contribute to prevention of cardiovascular complications and early death [
14,
15]. Given its prominent role in the development of pre-diabetes or diabetes, several studies further found the AIP was also an excellent predictor for risk of CVD among participants with abnormal glucose metabolism [
16,
17]. However, it is unclear whether the level of AIP control influences further CVD incidence in participants with diabetes and prediabetes. Accordingly, our study aim to investigate the association between AIP control level with risk of CVD in individuals with abnormal glucose metabolism by using data from the China Health and Retirement Longitudinal Study (CHARLS).
Discussion
To our knowledge, this is the first study to revealed a linear association between AIP control level with future stroke in middle-aged and elderly Chinese people with abnormal glucose metabolism, which demonstrated the worst control of AIP was a strong predictor of incident CVD among individuals with diabetes or pre-diabetes.
It is believed that there is a substantial correlation between AIP and LDL particle size [
7]. It has been shown that the primary underlying cause of cardiovascular disorders including acute coronary syndrome and stroke is atherosclerosis [
23]. And the onset and progression of atherosclerosis are determined by the quantity and size of LDL particles [
24]. This is consistent with our secondary outcomes AIP and stroke findings that the risk of stroke increases with increasing AIP clustering. Second, AIP was also significantly associated with FERHDL [
7], Fractional esterification rate of HDL cholesterol (FERHDL) was defined as the percentage of HDL free cholesterol (HDLFC) after depletion of apolipoprotein b during HDL development [
5]. and a clinical trial confirmed an association between FERHDL and cardiovascular disease risk factors [
25]. Another study showed that FERHDL and LDL particle size were predictors of insulin resistance [
26,
27]. It is widely recognized that insulin resistance is a significant risk factor for cardiovascular disease in addition to being a prevalent underlying cause of diabetes [
28,
29]. Therefore, it was shown that among people with diabetes or pre-diabetes, controlling AIP was a reliable predictor of incident CVD.
The results of this study showed that in the long-term follow-up, the AIP of class 2 was higher than that of class 3 and class 4 in the early stage, but that as time went on, it showed a declining trend and a commensurate decline in the risk of CVD. This implies that AIP is an indicator that can be controlled. Even if participants had high baseline AIP levels, when AIP levels were reduced after some intervention, the risk of later CVD also decreased. AIP was lowered by 57.85% and the incidence of hypercholesterolemia was dramatically decreased when the diabetic rats in the rat experiment were given lipid-lowering and hypoglycemic therapy [
30]. Given that individuals with diabetes and prediabetes have greater AIP levels, these investigations provide additional support for our findings. It is even more necessary to control AIP levels to reduce the risk of cardiovascular disease. Therefore, AIP is considered to be an indicator with a strong association with diabetes and CVD, which can predict the risk of developing CVD with diabetes or pre-diabetes. However, further high-quality prospective trials are needed to confirm our findings.
We then discovered that the correlation between cumulative AIP and CVD produced some intriguing findings. The risk of CVD increases with increasing AIP level, despite the long-established linear association between AIP and CVD [
31]. According to our research, people who have abnormal glucose metabolism may have a higher tolerance for cumulative AIP. There are also studies that show that when an individual’s AIP < 0.11, the risk of CVD is low, while the risk between 0.11 and 0.21 is medium, > 0.21 is high risk [
31]. Interestingly, the risk of CVD is different for people with different levels of control. In the results of this study, for people with good AIP control level such as class1 and 2, the OR value decreased with the increase of cumulative AIP. However, for the poor AIP control level of class3-5, the OR values tended to increase, and the risk of CVD development varied significantly with the level of AIP control.
Subgroup analysis revealed that based on class1, class3-5 showed a higher risk of CVD in agricultural residence location (53 < Age < 61 years) and smoking patients compared to other subgroups. Previous evidence has long been clear that smoking, alcohol consumption and BMI are associated with the risk of CVD [
32]. According to epidemiological studies, regular exercise protects against cardiovascular disease and type 2 diabetes, as well as the risk of death [
33]. For example, 12 weeks of aerobic Nordic walking can reduce AIP levels in middle-aged men with impaired blood sugar regulation, thereby reducing the risk of developing diabetes and complications [
34]. By modifying one’s diet, for as by eating enough peanuts, also can lower their risk of developing AIP and coronary heart disease [
35].
Our study has various advantages. First, there are few studies on the relationship between AIP and new-onset CVD in people with abnormal glucose metabolism, and we are the first study to use cluster analysis to classify changes in AIP. The population was divided into well-controlled and poorly controlled groups based on the level of AIP change, and it was found that reducing AIP significantly reduced the incidence of cardiovascular events. Second, we used data from large-scale national longitudinal surveys and adjusted for multiple confounders, which can reflect the inner association between AIP control level and new-onset CVD in participants with chronic glucose metabolism abnormalities. Third, our study suggests that AIP, as an indicator of low cost and convenience, may have clinical implications for the treatment of new-onset CVD in patients with abnormal glucose metabolism. Moreover, these biochemical parameters can be conveniently obtained from a single sample at the same time, potentially improving the long-term prognosis of participants with abnormal glucose metabolism.
Our study also has limitations. First, due to the limited sample size, the sampling error is large, which may affect the accuracy and stability of the relationship between AIP and new-onset CVD in people with abnormal glucose metabolism. Second, after the exclusion of TG and HDL-C measurement individuals, it will lead to the loss of diabetic metabolic population, which may have an impact on the results. Third, the participants in this study were exclusively from China. While the findings may have broader implications, confirmation through similar studies is needed for global clinical guidelines. Fourth, the diagnosis of CVD is self-reported physician’s diagnosis, lacking further CVD event adjudication was performed in those individuals who responded that they had had a CVD event. Fifth, there was still 207 patients without CVD data in the 2018 excluded in our final analysis. Fortunately, the proportion of lost to follow-up is statistically acceptable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.